Clinical staging of prostatic cancer: new modalities.
Carcinoma of the prostate gland is currently recognized as being the third leading cause of death by cancer in American men. As in other neoplastic disease processes, the institution of adequate treatment depends on the clinical stage of the disease. Radionuclide bone scans, pelvic lymphangiography, computed tomography, and prostatic ultrasonography are relatively new imaging modalities currently available to help improve the accuracy of the clinical staging process.
D000230:Adenocarcinoma / Q000473:pathology* / Q000556:secondary; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D001842:Bone and Bones / Q000000981:diagnostic imaging; D002277:Carcinoma / Q000473:pathology* / Q000556:secondary; D004998:Ethiodized Oil; D006801:Humans; D008207:Lymphatic Metastasis; D008208:Lymphatic System / Q000033:anatomy & histology; D008220:Lymphography; D008297:Male; D009367:Neoplasm Staging / Q000379:methods*; D010388:Pelvis / Q000000981:diagnostic imaging; D011122:Polyphosphates; D011467:Prostate / Q000033:anatomy & histology; D011469:Prostatic Diseases / Q000175:diagnosis; D011470:Prostatic Hyperplasia / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000473:pathology*; D011877:Radionuclide Imaging; D013667:Technetium; D017556:Technetium Compounds; D014057:Tomography, X-Ray Computed; D014463:Ultrasonography
D011122:Polyphosphates; D017556:Technetium Compounds; C009835:technetium Tc 99m polyphosphate; D013667:Technetium; D004998:Ethiodized Oil